Evidence map›Paper›PMID 41683577›Full record

ReviewInternational journal of molecular sciences2026

The Immune Biology of the Adrenal Gland Microenvironment and Its Role in Metastatic Progression.

Natalie M Liu, Cyrus J Sholevar, Makan Karimzadeh, Jay Uppuluri, Clemens Van Dongen, Claire E Graves, Michael J Campbell, Anthony E Zamora, Sean J Judge, Robert J Canter

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Natalie M LiuDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Cyrus J SholevarDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.ORCID 0009-0002-7772-4229
Makan KarimzadehDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Jay UppuluriDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Clemens Van DongenDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Claire E GravesDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0002-1974-2384
Michael J CampbellDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Anthony E ZamoraDepartment of Internal Medicine, School of Medicine, University of California Davis, Davis, CA 95616, USA.
Sean J JudgeDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.
Robert J CanterDivision of Surgical Oncology, Department of Surgery, UC Davis Medical Center, University of California Davis, Sacramento, CA 95817, USA.ORCID 0000-0002-3331-5418

Funding

NIH HHS 1T32CA251007
6 · The paper itself

Abstract

Metastatic lesions are the most common malignant tumor of the adrenal gland. While surgery can have a favorable surgical outcome for isolated adrenal metastatic lesions, most adrenal metastases occur in the context of disseminated disease, and the overall prognosis remains poor. Although data are limited, metastatic lesions from diverse solid tumors to the adrenal gland have typically demonstrated poor response to immunotherapy, particularly immune checkpoint inhibitors with programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade. This apparent resistance to immunotherapy suggests that the adrenal gland microenvironment may be influenced by local microenvironmental factors, resulting in an organ microenvironment that is immune tolerant and permissive to tumor growth. However, the current literature on the adrenal gland immune microenvironment is limited, underscoring the need for better understanding of the immunobiology of this critical endocrine organ. Thus, the current scarcity of scientific studies on this topic is a novel opportunity to investigate and develop innovative treatment strategies for adrenal solid cancer metastases. In this literature review, we summarize the available data published on the immunobiology of the adrenal gland and the potential local immune mechanisms that may be contributing to the adrenal gland's role in promoting resistance to otherwise breakthrough immunotherapy treatments.

Indexed as

Adrenal Gland NeoplasmsAdrenal GlandsTumor MicroenvironmentAnimalsDisease ProgressionHumansImmunotherapyNeoplasm Metastasisadrenal glandadrenal metastasesimmunotherapytumor microenvironment

Identifiers

PMID41683577
PMCPMC12897121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.